Sutro Biopharma (STRO) Operating Leases (2021 - 2025)

Sutro Biopharma (STRO) has 5 years of Operating Leases data on file, last reported at $7.9 million in Q4 2025.

• For the quarter ending Q4 2025, Operating Leases fell 49.66% year-over-year to $7.9 million; the trailing twelve-month figure through Dec 2025 stood at $7.9 million (down 49.66% YoY), and the FY2025 full-year result was $7.9 million, down 49.66% from the prior year.
• Operating Leases eased to $7.9 million in Q4 2025, from $9.7 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $32.1 million in Q3 2021 to a low of $7.9 million in Q4 2025.
• A 5-year average of $22.6 million and a median of $24.0 million in 2023 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases retreated 3.23% in 2022 and slumped 49.66% in 2025, its largest moves.
• Tracing STRO's Operating Leases over 5 years: stood at $31.2 million in 2021, then fell by 5.28% to $29.6 million in 2022, then fell by 21.71% to $23.2 million in 2023, then tumbled by 32.31% to $15.7 million in 2024, then tumbled by 49.66% to $7.9 million in 2025.
• Business Quant data shows STRO's Operating Leases at $7.9 million in Q4 2025, $9.7 million in Q3 2025, and $11.5 million in Q2 2025.